Standard Risk B-precursor Acute Lymphoblastic Leukemia
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Folinic acid (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Pegaspargase (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Doxorubicin; Doxorubicin; Mercaptopurine; Tioguanine; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 11 Jun 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results assessing clinical, and outcome data for Down syndrome and non-Down syndrome from AALL0331, AALL0932, AALL0232 and AALL1131, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 10 Apr 2020 Results from AALL0331(n=5195) and AALL0232 (n=3001) assessing Impact of Asparaginase Discontinuation and Erwinia as a substitution on Outcome in Childhood Acute Lymphoblastic Leukemia, published in the Journal of Clinical Oncology